Genentech secures FDA accelerated approval for Polivy, BR combo for DLBCL

This article was originally published here

The accelerated approval for the Polivy, BR combination is for treatment of adult patients with DLBCL whose condition is either relapsed or refractory (R/R) and had been subjected

The post Genentech secures FDA accelerated approval for Polivy, BR combo for DLBCL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply